Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
=== Skin cancers === MCH has been identified in both melanoma and squamous cell carcinoma cell lines. However, pro-MCH, a precursor to MCH, has not been found in melanocytes, keratinocytes, or fibroblasts, which might indicate MCH might be brought into these cells by macrophages as part of the immune response. More research is needed to fully determine and understand any relationship between MCH and possible immune responses in skin.
== Pharmaceutical and legal impact == In the United States, the first company to develop a drug ("pioneer") must demonstrate that the drug is safe and effective by extensive and expensive trials. After that, there would be a period of exclusive rights to sell the drug, after which other companies ("generics") can market the same drug as a generic chemical under the Abbreviated New Drug Application. The pioneer companies often attempt to evergreen the patent drug by many methods. Since the appearance of generics can decrease the revenue rate of patented drugs by as much as 80%, this is very profitable. When disappearing polymorphs are involved, it is sometimes true that the pioneer company first discovered and patented polymorph A, then polymorph B, but polymorph A inevitably converts to polymorph B when seeded with microscopic amounts of B. This then means that later companies, even if they follow all the steps specified by the pioneering patent, end up with a polymorph B. Since with disappearing polymorphism, it is practically impossible for anyone to produce the original drug without it turning into the new one, producers are effectively barred from selling generics until the patent for the new polymorph has run out. Alternatively, they may try to argue that a new polymorph needs to undergo the same trials as new drugs, potentially delaying release of a generic for years.
females: 5 ng/L or pg/mL males: 12 ng/L or pg/mL children under 6 months of age: 40 ng/L or pg/mL children between 6 months and 3 years of age: 15 ng/L or pg/mL When over 3 years of age, adult cutoffs may be used A Cochrane systematic review assessed the diagnostic accuracy of basal and stimulated calcitonin for Medullary Thyroid cancer. Although both basal and combined basal and stimulated calcitonin testing presented high accuracy (sensitivity: between 82% and 100%; specificity: between 97.2% and 100%), these results had a high risk of bias due to design flaws of included studies. Overall, the value of routine testing of calcitonin for diagnosis and prognosis of Medullary Thyroid Cancer remains uncertain and questionable. Increased levels of calcitonin have also been reported for various other conditions. They include: C-cell hyperplasia, nonthyroidal oat cell carcinoma, nonthyroidal carcinoma and other nonthyroidal malignancies, acute kidney injury and chronic kidney failure, hypercalcemia, hypergastrinemia, and other gastrointestinal disorders, and pulmonary disease.
=== Opioid overdose === Naloxone is used for the emergency treatment of an overdose. It can be given by many routes (e.g., intramuscular (IM), intravenous (IV), subcutaneous, intranasal, and inhalation) and acts quickly by displacing opioids from opioid receptors and preventing the activation of these receptors. Naloxone kits are recommended for laypersons who may witness an opioid overdose, for people with large prescriptions for opioids, those in substance use treatment programs, and those recently released from incarceration. Since naloxone is a life-saving medication, many areas of the U.S. have implemented standing orders for law enforcement to carry and give it as needed. In addition, naloxone can be used to challenge a person's opioid abstinence status before starting a medication such as naltrexone, which is used in the management of opioid addiction. Good Samaritan laws typically protect bystanders who administer naloxone. In the U.S., at least 40 states have Good Samaritan laws to encourage bystanders to take action without fear of prosecution. As of 2019, 48 states give pharmacists the authority to distribute naloxone without an individual prescription. Homicide, suicide, accidents and liver disease are also opioid-related causes of death for those with OUD. Many of these causes of death are unnoticed due to the often limited information on death certificates.
Sources: en.wikipedia.org
== Further reading == Cook, E.M, and DuMont, H.D. (1991) Process Drying Practice, McGraw-Hill, Inc., ISBN 0-07-012462-0 Keey, R.B., (1992). Drying of Loose and Particulate Materials 1st ed., Taylor & Francis, ISBN 0-89116-878-8 Nutritional evaluation of food processing second edition (1975), Robert S. Harris, Ph.D. and Endel Karmas Ph.D. (eds) Filková, I., & Mujumdar, A. S. (2020). Industrial spray drying systems. In Handbook of industrial drying (pp. 263-307). CRC Press. Jafari, S. M., Arpagaus, C., Cerqueira, M. A., & Samborska, K. (2021). Nano spray drying of food ingredients; materials, processing and applications. Trends in Food Science & Technology, 109, 632-646. Klimša, V., Ruphuy, G., Jonáš, J., Mašková, L., Kašpar, O., Žvátora, P., & Štěpánek, F. (2023). Spray drying robot for high-throughput combinatorial fabrication of multicomponent solid dispersions. Powder Technology, 428, 118872.
His season high for strikeouts that year was just seven, achieved in a complete game, four-hit, 4–1 victory over Chicago on September 10. In 30 games (29 starts), he had a 10–14 record, 80 strikeouts, and 91 walks in 189+2⁄3 innings pitched. His 14 losses tied with Bob Friend, Roberts, and Curt Simmons for third in the league (behind Kline's 16 and Johnny Podres's 15), but his 3.42 ERA ranked eighth. Sports Illustrated reported, "Mizell and [Larry] Jackson had impressive ERAs between them but lost more than they won." After working out at the YMCA across from Busch Stadium during the 1958–59 offseason, Mizell showed a stronger fastball in 1959. He did not pitch at the beginning of spring training as he negotiated for a new contract, but he wound up settling for $17,000, his salary each of the previous two seasons. On May 15, he had a season-high 10 strikeouts, allowing just four hits and two unearned runs in an 8–2 victory over the Phillies. He had eight strikeouts in the second game of a doubleheader against Philadelphia on June 7, limiting the Phillies to five hits in a 2–0 shutout victory. In the first half of the season, he enjoyed a 9–3 record and a 3.05 ERA. He was named to both National League All-Star teams in 1959 (in those days, two All-Star games were played in a season). However, he did not appear in either game. The second half of the season saw him post a 4–7 record and a 5.94 ERA. On July 19, 1959, Mizell allowed three runs over seven innings to defeat the Braves, 9–5.
=== Story === The game features three different playable characters, each with their own story arcs that intersect throughout the game: Arthur's Story: Arthur Hastings (Alex Wyndham) works as a censor approving or redacting old news articles from Wellington Wells' Department of Archives, Printing, and Recycling. While working, he comes across a news clipping of him and his older brother Percy (Bradley Henderson) after World War II. At this point, Arthur can either take his Joy (which ends the game) or refuse it, wanting to remember Percy. If the latter choice is taken, Arthur attends an office party with his boss, Victoria Byng (Katherine Kingsley), and watches in horror as Victoria and his co-workers consume a rat that they hallucinate to be a candy-filled piñata. He is then called out as a Downer and chased by two police constables, ending up in the Garden District, now populated by Wastrels. Arthur resolves to escape Wellington Wells and find Percy. With the assistance of various characters, Arthur works his way through the districts uncovering certain truths along the way. It is eventually revealed that the "Very Bad Thing" was when the population of Wellington Wells turned over all children under the age of 13 years to the Germans in exchange for their freedom. Arthur discovers that the German tanks used to threaten the town into compliance were actually dummy tanks made of papier-mâché, and that while the populace could have resisted, they did not out of fear.
== Production == Red yeast rice is produced by cultivating the mold species Monascus purpureus on rice for 3–6 days at room temperature. The rice grains turn bright red at the core and reddish purple on the outside. The fully cultured rice is then either sold as the dried grain, or cooked and pasteurized to be sold as a wet paste, or dried and pulverized to be sold as a fine powder. China is the world's largest producer of red yeast rice, but European companies have entered the market.
==== Resistance exercise and muscle atrophy ==== Resistance exercise is exercising a muscle or muscle group against external resistance (see strength training). Studies have found that: a) mice feeding on a high fat or normal diet and given the resistance exercise of repeatedly climbing up a 1 meter ladder for 40 minutes had higher levels of α-ketoglutarate in their blood and seven muscles than non-exercising mice feeding respectively on the high fat or normal diet; b) mice conducting ladder climbing for several weeks and eating a high fat diet developed lower fat tissue masses and higher lean tissue masses than non-exercising mice on this diet; c) mice not in exercise training fed α-ketoglutarate likewise developed lower fat tissue and higher lean tissue masses than α-ketoglutarate-unfed, non-exercising mice; d) OXGR1 was strongly expressed in the mouse adrenal gland inner medullas and either resistance training or oral α-ketoglutarate increased this tissue's levels of the mRNA that is responsible for the synthesis of OXGR1; e) α-ketoglutarate stimulated chromaffin cells isolated from mouse adrenal glands to release epinephrine but reduction of these cells' OXGR1 levels by small interfering RNA reduced this response; f) α-ketoglutarate increased the blood serum levels of epinephrine in mice expressing OXGR1 but not in Oxgr1 gene knockout mice (i.e., mice lacking the OXGR1 gene and protein); g) mice on the high fat diet challenged with α-ketoglutarate increased their blood serum levels of epinephrine and developed lower fat tissue masses and higher lean tissue masses but neither OXGR1 gene knockout mice nor mice that had only their adrenal glands' OXGR1 gene knocked out showed these responses; and h) OXGR1 gene knockout mice fed the high fat diet developed muscle protein degradation, muscle atrophy (i.e., wasting), and falls in body weight whereas control mice did not show these fat diet-induced changes. These findings indicate that in mice resistance exercise increases muscle production as well as serum levels of α-ketoglutarate which in turn suppresses diet-induced obesity (i.e., low body fat and high lean body masses) at least in part by stimulating the OXGR1 on adrenal gland chromaffin cells to release epinephrine. Additional mechanisms include inhibition of hepatic gluconeogenesis via serpina1e signaling (reducing hyperglycemia) and activation of the PHD3/ADRB2 pathway in muscle cells. Supplementation studies have shown that oral α-ketoglutarate increases serum levels of α-ketoglutarate, suppresses obesity and improves glucose tolerance in mice. See § Glucose tolerance below.
Sources: en.wikipedia.org
1993/3156) European Communities (Definition of Treaties) (European Investment Fund) Order 1993 (S.I. 1993/3157) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) (No. 2) Order 1993 (S.I. 1993/3158) Environment and Safety Information (Northern Ireland) Order 1993 (S.I. 1993/3159) Roads (Northern Ireland) Order 1993 (S.I. 1993/3160) Merchant Shipping (Fire Protection) (Non-United Kingdom) (Non-SOLAS Ships) (Amendment) Rules 1993 (S.I. 1993/3161) Merchant Shipping (Fire Appliances) (Amendment) Regulations 1993 (S.I. 1993/3162) Merchant Shipping (Fire Protection) (Amendment) Regulations 1993 (S.I. 1993/3163) Merchant Shipping (Fire Protection) (Ships Built Before 25 May 1980) (Amendment) Regulations 1993 (S.I. 1993/3164) Water and Sewerage Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/3165) Ministerial and other Salaries Order 1993 (S.I. 1993/3166) Redundancy Payments (National Health Service) (Modification) Order 1993 (S.I. 1993/3167) Finance Act 1985 (Interest on Tax) (Prescribed Rate) (No. 2) Order 1993 (S.I. 1993/3168) Local Government Act 1992 (Commencement No. 3) Order 1993 (S.I. 1993/3169) Town and Country Planning (Fees for Applications and Deemed Applications) (Amendment) Regulations 1993 (S.I. 1993/3170) Taxes (Interest Rate) (Amendment No. 4) Regulations 1993 (S.I. 1993/3171) National Health Service (General Dental Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/3172) Commercial Agents (Council Directive) (Amendment) Regulations 1993 (S.I.
Okcuoglŭ, A.; Arcasoy, A.; Minnich, V.; Tarcon, Y.; Cin, S.; Yörükoğlu, O.; Demirag, B.; Renda, F. (August 1966). "Pica in Turkey. 1. The incidence and association with anemia". The American Journal of Clinical Nutrition. 19 (2): 125–131. doi:10.1093/ajcn/19.2.125. ISSN 0002-9165. PMID 5222998. Minnich, V.; Okçuoğlu, A.; Tarcon, Y.; Arcasoy, A.; Cin, S.; Yörükoğlu, O.; Renda, F.; Demirağ, B. (January 1968). "Pica in Turkey. II. Effect of clay upon iron absorption". The American Journal of Clinical Nutrition. 21 (1): 78–86. doi:10.1093/ajcn/21.1.78. ISSN 0002-9165. PMID 5237295. Glutathione synthesis
Cocaine overdose may cause seizures, abnormally high body temperature and a marked elevation of blood pressure, which can be life-threatening, abnormal heart rhythms, and death. Anxiety, paranoia, and restlessness can also occur, especially during the comedown. With excessive dosage, tremors, convulsions, and increased body temperature are observed.
=== Genetic engineering === Magnetic nanoparticles can be used for a variety of genetics applications. One application is the rapid isolation of DNA and mRNA. In one application, the magnetic bead is attached to a poly T tail. When mixed with mRNA, the poly A tail of the mRNA will attach to the bead's poly T tail and the isolation takes place simply by placing a magnet on the side of the tube and pouring out the liquid. Magnetic beads have also been used in plasmid assembly. Rapid genetic circuit construction has been achieved by the sequential addition of genes onto a growing genetic chain, using nanobeads as an anchor. This method has been shown to be much faster than previous methods, taking less than an hour to create functional multi-gene constructs in vitro.
Degenerative disc disease (DDD) is a medical condition typically brought on by the aging process in which there are anatomic changes to and/or loss of function of one or more intervertebral discs of the spine. DDD can take place with or without symptoms, but is typically identified once symptoms arise. The root cause is thought to be loss of soluble proteins within the fluid contained in the disc, with resultant reduction of the oncotic pressure, which in turn causes loss of fluid volume. Normal downward forces cause the affected disc to lose height, and the distance between vertebrae is reduced. The anulus fibrosus, the tough outer layer of a disc, also weakens. This loss of height causes laxity of the longitudinal ligaments, which may allow anterior, posterior, or lateral shifting of the vertebral bodies, causing facet joint malalignment and arthritis; scoliosis; cervical hyperlordosis; thoracic hyperkyphosis; lumbar hyperlordosis; narrowing of the space available for the spinal tract within the vertebra (spinal stenosis); or narrowing of the space through which a spinal nerve exits (vertebral foramen stenosis), with resultant inflammation and impingement of a spinal nerve, causing a radiculopathy. DDD can cause mild to severe pain, either acute or chronic, near the involved disc, as well as neuropathic pain if an adjacent spinal nerve root is involved. Diagnosis is suspected when typical symptoms and physical findings are present and confirmed by X-rays of the vertebral column.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.